Prognostic factors for supraglottic laryngeal carcinoma: Importance of the unfit patient
Head & Neck, 06/26/2012

1 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology, April 15, 2013    Clinical Article

2 Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer: a randomized biomarker pilot study Clinical Cancer Research, May 6, 2013    Clinical Article

3 Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer Journal of the National Cancer Institute, May 1, 2013    Clinical Article

4 Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma Annals of Oncology, May 6, 2013    Clinical Article

5 Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles The Lancet, April 23, 2013    Clinical Article

6 Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial The Lancet Oncology, May 17, 2013    Clinical Article

7 Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial The Lancet Oncology, May 3, 2013    Clinical Article

8 Association of metformin use with cancer incidence and mortality: A meta-analysis Cancer Epidemiology, April 22, 2013    Review Article

9 Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial European Journal of Cancer, April 2, 2013    Clinical Article

10 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, May 3, 2013    Clinical Article

11 Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors Cancer, April 12, 2013    Clinical Article

12 Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA Trial Journal of Clinical Oncology, April 25, 2013    Clinical Article

13 Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study The Lancet Oncology, May 3, 2013    Clinical Article

14 AVEREL: A randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer Journal of Clinical Oncology, April 15, 2013    Clinical Article

15 Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Childrens Research Hospital experience Cancer, May 2, 2013

16 Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial analysis Journal of Clinical Oncology, April 30, 2013    Clinical Article

17 Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer British Journal of Cancer, May 7, 2013    Clinical Article

18 Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis Journal of the National Cancer Institute, April 19, 2013    Evidence Based Medicine

19 Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study Journal of Clinical Oncology, April 29, 2013    Clinical Article

20 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, April 23, 2013    Clinical Article